Follicum announced on September 17, 2019 that the Company had received a so-called Notice of Allowance from the US Patent and Trademark Office (“USPTO”) regarding the patent application “Novel Compositions and Uses Thereof”. Follicum today announces that the patent has now formally been granted by the USPTO. The patent number is US 10,517,932 and the patent is valid until 2032.
In this patent family, Follicum already has two granted US patents covering different aspects of FOL-005. Follicum has subsequently submitted a follow-up, so called Continuing Patent Application, which extends and broadens the protection around the therapeutic use of FOL-005. Follicum has now received a formal grant for this follow up application. The patent provides protection in the United States until the year 2032. The USPTO will publish the granted patent on December 31, 2019.
CEO Jan Alenfall comments:
– The United States is one of the largest markets for Follicum, and hence this patent is of major importance to us and an important step in our global patent strategy. We are continuously working to strategically expand our patent portfolio in our key markets.
FOL-005 is a modified, short version of the endogenous protein, osteopontin. In two completed clinical studies, treatment with FOL-005 has been shown to be effective and safe. The first study was done in healthy volunteers while the other one was conducted in alopecia patients, i.e. in men with incipient baldness. In both studies, patients were treated at the clinic with intradermal injections, 2 or 3 times a week. Planning for a phase II study is currently underway aiming at investigating the hair-stimulating effect of daily treatment with different doses of the new topical formulation.
For further information, please contact:
Jan Alenfall – CEO, Follicum AB
Telephone: +46 46 19 21 97
This information is information that Follicum is obliged to make public according to the EU Market Abuse Regulation. The information was provided through the agency of the contact persons above, for publication on the 16th of December 2019.
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. www.follicum.com.